Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis
Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis
About this item
Full title
Author / Creator
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
Several major randomized control studies have demonstrated that mepolizumab, an anti-IL-5 monoclonal antibody, is effective for patients with severe eosinophilic asthma who show exacerbation or require systemic corticosteroid maintenance therapy. However, the predictive factors of the response to mepolizumab other than blood eosinophil count are un...
Alternative Titles
Full title
Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_15a0fc23ace545159587a6dcd813756e
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_15a0fc23ace545159587a6dcd813756e
Other Identifiers
ISSN
1471-2466
E-ISSN
1471-2466
DOI
10.1186/s12890-019-0952-1
